Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00495209
Other study ID # 2005-0876
Secondary ID
Status Completed
Phase
First received
Last updated
Start date July 26, 2006
Est. completion date March 7, 2018

Study information

Verified date August 2018
Source M.D. Anderson Cancer Center
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The use of complementary and alternative medicine (CAM) in the United States has increased dramatically in the past 10 years. Nowhere is this trend more apparent than when one examines CAM use by patients diagnosed with cancer. As with the general population, patients with cancer typically use CAM-based modalities alongside their conventional cancer treatments. Patients are often seeking a holistic approach to managing and preventing disease. Although most patients will combine alternative approaches with conventional medicine, some patients do in fact decline curative conventional treatments in favor of more non-toxic alternative approaches. One such approach that patients combine with conventional medicine or use in place of conventional medicine is qigong.

Qigong is a bioenergy therapy with a long history of therapeutic use for many diseases, including cancer. Preliminary experiments and a review of the literature show that qigong might improve the outcome for cancer patients. However, none of this research has been confirmed in the peer-reviewed Western scientific literature. Although it is unlikely that EQT will result in significant decreases in tumor size, patients are using qigong either as a complementary approach, and sometimes even in place of conventional medicine, it is, therefore, important for us to determine whether there is any merit to this treatment modality. The goal of this pilot trial is to examine one form of medical qigong (external qi therapy (EQT)) to determine feasibility. In an exploratory nature we will also examine any changes in tumor size in women with breast cancer who are awaiting surgery.


Description:

Some research has been done on the human body to learn about how it may exist within an electromagnetic (energy with electric and magnetic parts) field. Some research has shown that changing the form of this field may have an effect on cell growth.

You will be asked to complete 3 questionnaires that ask about your quality of life (QOL), your physical functioning, and any symptoms you may be having. The questionnaires will take about 15 to 20 minutes to complete. You will also have a physical exam. If you have had mammogram and ultrasound less than one week after your core biopsy, you will need to have a repeat mammogram and ultrasound to check the size of your tumor.

You will then be scheduled for a total of 5 EQT sessions (1 session per day for 5 consecutive days). You will meet with an expert in EQT (qigong master) to conduct the sessions. During each session, the qigong master will send forth qi (energy) focused toward helping to improve patients' physical and mental functioning. The qigong master will do this by placing his hands over the affected area and emitting his energy into your body. He will not touch you, but will say a few words. These comments will be spoken in Chinese and may be translated into English by a translator. The sessions may be conducted in a group setting. After each session, you will have a physical exam. Each session will last about 30 minutes.

Once you have completed all the sessions, you will have a follow-up visit. During this visit, you will have a physical exam and a mammogram and ultrasound to check the size of your tumor. You will also be asked to complete 3 more questionnaires that will ask the same questions as before. The questionnaires will take about 15 to 20 minutes to complete.

In order to find out if women are willing to have EQT, researchers will keep track of how many people are asked to join the study and how many decide to participate. If you consent to participate, the study staff will keep track of the EQT sessions you attend, if you complete the questionnaires, and if you provide the optional blood samples.

Your participation in this study will be over after your follow-up visit.

This is an investigational study. The baseline mammogram and ultrasound are standard of care. All questionnaires and the follow-up mammogram and ultrasound are for research purposes. Up to 10 patients will take part in this study. All will be enrolled at M. D. Anderson or Fudan University Cancer Hospital.


Recruitment information / eligibility

Status Completed
Enrollment 7
Est. completion date March 7, 2018
Est. primary completion date March 7, 2018
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. Histologically confirmed and intact invasive ductal carcinoma

2. Women with a single measurable mass less than or equal to 3 cm

3. Women who are awaiting the surgical removal of breast cancer

4. Surgery is scheduled at least 2 weeks from the time of recruitment

5. Willing to come to MDACC or Fudan University Cancer Hospital (FUCH) for 5 consecutive days to receive the EQT

6. 18 years of age or older because the assessment tools are not validated for use in minors.

Exclusion Criteria:

1. Women with lobular carcinoma

2. Prior or planned neoadjuvant treatment with chemotherapy or radiotherapy

3. Evidence of metastatic disease

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Qigong
EQT daily for 5 consecutive days prior to surgery.

Locations

Country Name City State
United States UT MD Anderson Cancer Center Houston Texas

Sponsors (1)

Lead Sponsor Collaborator
M.D. Anderson Cancer Center

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Feasibility of conducting external qigong in women with breast cancer awaiting surgery 3 Years
Secondary Initial efficacy of external qi therapy (EQT) as measured by tumor size Baseline to end of treatment (5 days)
See also
  Status Clinical Trial Phase
Recruiting NCT04681911 - Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer Phase 2
Terminated NCT04066790 - Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer Phase 2
Completed NCT04890327 - Web-based Family History Tool N/A
Completed NCT03591848 - Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility N/A
Recruiting NCT03954197 - Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients N/A
Terminated NCT02202746 - A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Phase 2
Active, not recruiting NCT01472094 - The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
Completed NCT06049446 - Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
Withdrawn NCT06057636 - Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study N/A
Recruiting NCT05560334 - A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations Phase 2
Active, not recruiting NCT05501769 - ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer Phase 1
Recruiting NCT04631835 - Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer Phase 1
Completed NCT04307407 - Exercise in Breast Cancer Survivors N/A
Recruiting NCT03544762 - Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation Phase 3
Terminated NCT02482389 - Study of Preoperative Boost Radiotherapy N/A
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Completed NCT00226967 - Stress, Diurnal Cortisol, and Breast Cancer Survival
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT06019325 - Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy N/A
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2

External Links